In radiology, AI is advancing faster than the field can keep up
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Regulatory reform can unlock access to biosimilars
Every day, I think about the patients waiting for medicines that could change, or even save, their lives.…
AI scribes make clinicians happy, but don’t save them a lot of time
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
First-generation mental health apps look to add next-gen AI chatbots
O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming…
Cognita CEO on next steps for vision language models in radiology
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Contributors to top psychiatry journals fail to disclose industry payments
Amid ongoing concern over conflicts of interest that may affect medical practice, a new study found that 14%…
We’re reading about Novo Alzheimer’s trials, Bayer stroke results
Good morning, Jason Mast here filling in for Ed. Happy turkey week to all. I, for one, have…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…
We’re reading about vaccine warnings, U.K. standoff with pharma
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes…
Countries used to test drugs often don’t see the approved medicines, study finds
Numerous medicines are not accessible in many of the countries where they were tested before approval by the…
We’re reading about Trump and patent policies, a new malaria drug
Top of the morning to you, and a fine one it is. Blue skies and comfortable breezes are…
Mark Cuban tries to shake up biosimilar pricing with a version of J&J’s Stelara
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company…